Asia-Pacific Biologics Market is expected to grow with the CAGR of 11.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-biologics-market

Asia-Pacific biologics market is a highly consolidated market. The market has witnessed increased strategic developments due to favorable market scenario.

Some of the major players dealing in Asia-Pacific biologics market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

F. Hoffmann-La Roche Ltd. is expected to dominate the Asia-Pacific biologics market. The other key players existing in the market includes are Biocon, BeiGene, Bharat Biotech, KM Biologics (A Subsidiary of Meiji Holdings Co., Ltd.), Shanghai Henlius Biotech, Inc., Biogen, BioDiem, Intas Pharmaceutical Ltd, YL Biologics, Innovent, FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Qilu Pharmaceutical Co., Ltd., Ipsen Pharma, AGC Biologics, Panacea Biotec, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Chime Biologics, Catalent, Inc., NBHL ltd., Cipla Inc., Celltrion Healthcare Co.,Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, AbbVie Inc., Bristol-Myers Squibb Company, WuXi Biologics, Johnson & Johnson Services, Inc., Evotech, Samsung Biologics among others.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. was founded in 1896 and is headquartered in Basel, Switzerland. The company is engaged in creating innovative medicines and diagnostics tests that help millions of people worldwide. It has following business segments: Pharmaceuticals, Diagnostics and the market focused segment is Pharmaceuticals. The company offers range of product categories including Pharmaceuticals, Solutions for Diagnostics, and Products for Researchers among others in which market focused category fall under Pharmaceuticals. The company is taking strategic initiatives to increase its portfolio.

• In June 2014, F. Hoffmann-La Roche Ltd launched a Cobas PIK3CA mutation test for patients with advanced or metastatic breast cancer in countries accepting the CE mark. This product launch has helped the company broaden its product portfolio and boosted market growth.

The company has global presence in North America, Europe, Africa, and Asia-Pacific. The company has many subsidiaries such as Roche Diagnostica Brasil Ltda. (Brazil), Roche Diabetes Care Brasil Ltda. (Brazil), Trophos SA (France), INSTITUT ROCHE SAS (France) and Roche Diagnostics K.K. (Japan) among others

Pfizer Inc.,

Pfizer Inc., was founded in 1849 and is headquartered in New York, U.S. The company focusses on providing standard for quality, safety and value in the discovery, development and manufacturing of health care products, including innovative medicines and vaccines. The company offers range of product categories BAVENCIO, BESPONSA for injection among others in which market focused category falls under BAVENCIO, BESPONSA for injection. The company is taking strategic initiatives to increase its product portfolio.

• In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.

The company has global presence in North America, Europe, Middle East and Africa, Asia-Pacific and South America. The company has many subsidiaries such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd ( Australia), Pfizer Dominicana, S.A.(Dominican Republic) and Pfizer Egypt S.A.E.(Egypt) among others.          

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company was founded in 1858 and is headquartered in New York, U.S. The company is focused on treating cancer, blood diseases, autoimmune and heart diseases during a remarkable time when unprecedented scientific discoveries are advancing the new treatments. The company offers product categories including The company is focused on treating cancer, blood diseases, autoimmune and heart diseases during a remarkable time when unprecedented scientific discoveries are advancing the new treatments in which the market focused category falls under EMPLICITI, OPDIVO, YERVOY, ZEPOSIA. The company is increasing its product portfolio such as:

• In October 2020, Bristol-Myers Squibb Company announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. This launch was a worldwide used treatment for cancer which benefited the company.

The company has global presence in the South America, North America, Europe and Asia-Pacific. The company has many subsidiaries such as Abilify. Atripla (U.S.), Avapro/Avalide(U.S.), Cabometyx, Inc. (U.S.), ENHANZE (U.S.), Yescarta Inc. (Australia) among others.